Merck announces EC approves SC administration of Keytruda for all adult indications approved in the European Union: Rahway, New Jersey Thursday, November 20, 2025, 14:00 Hrs [IST] ...

Akeso has a validated process in place for developing antibodies but does require US exposure to meet its lofty valuation.

Only one clinical-stage asset from the ProfoundBio acquisition remains in development: The antibody-drug conjugate Rina-S, in ...

Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more ...

Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a ...

Jazz Pharmaceuticals and Zymeworks announced positive topline phase 3 results for Ziihera in HER2-positive GEA. Click here to ...

Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, gaining access to an experimental flu drug in its ...

The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...

Pfizer is launching the first clinical trials for its PD-1xVEGF drug, while Akeso detailed the first overall survival win for ...

Merck & Co. Inc. is buying Cidara Therapeutics Inc. for $9.2 billion to acquire a late-stage flu candidate and also to outrace blockbuster Keytruda’s looming patent expiration. CD-388, Cidara’s lead ...

Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell ...

Finance Income, net, was $0.1 million for the three months ended September 30, 2025, compared to $1.5 million in the same ...